ZEZekeriya Ervatan

Zekeriya Ervatan

*This is an algorithmically generated author record based on publicly available information.

Zekeriya Ervatan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of factors affecting therapeutic levetiracetam drug levels in intensive care unit patients: a retrospective study

    by Yunus Emre Ayhan, Rabia Sari Küçük, Zekeriya Ervatan, Muhammed Yunus Bektay

  • Open Access

    Changes in the microbial spectrum and antimicrobial resistance of bloodstream infections in intensive care units before and during the COVID-19 pandemic

    by Sümeyye Bayram, Funda Şimşek, Çiğdem Arabacı, Zekeriya Ervatan

    Bloodstream infections (BSIs) are major infectious conditions associated with high morbidity and mortality, particularly in intensive care units (ICUs). In

  • Open Access

    A Nurse‐Led Approach to Preventing Delirium in the ICU : A Randomised Controlled Trial of NICE Guideline‐Based Sensory Modulation

    by Serpil Topçu, Melis Şen Yılmaz, Merve Kıymaç Sarı, Dilek Özdemir Ürkmez, Zekeriya Ervatan

    Background: Delirium is a preventable yet pervasive complication in intensive care units (ICUs) settings, disproportionately increasing patient morbidity and healthcare costs. While environmental disruptions (e.g., light/noise) are modifiable risk factors, nurse‐delivered, non‐pharmacological strategies may be under‐implemented in routine practice despite guideline recommendations. Aim: This study aimed to evaluate the efficacy of a simple, holistic nursing intervention—eye masks and earplugs—to mitigate delirium incidence in ICU patients. Study Design: A randomised controlled trial was conducted in the adult general intensive care unit of a public hospital in Istanbul, Türkiye, between May and September 2024. Patients were assigned to either an intervention group (nightly use of eye masks and earplugs together with a delirium prevention guide) or a control group (delirium prevention guide only). Delirium was assessed using the Richmond Agitation Sedation Scale (RASS) and the Nursing Delirium Screening Scale (Nu‐DESC). Results: In total, 190 patients were randomised. Ten participants allocated to the intervention group did not receive the intervention because 9 were unwilling to continue and 1 became intubated. Consequently, 180 patients were analysed (90 per group). The intervention group showed a 62% lower incidence of delirium than the control group (7.8% vs. 20%, p = 0.001). In addition, delirium developed later in the intervention group (2.57 ± 0.79 vs. 1.89 ± 0.85 days, p = 0.001), and Nu‐DESC scores differed significantly between the groups ( p = 0.001). Conclusions: Nightly use of eye masks and earplugs was associated with lower delirium incidence and later onset in ICU patients when implemented alongside a NICE‐aligned delirium prevention guide. Relevance to Clinical Practice: As a scalable, non‐pharmacological approach, this intervention offers a feasible, low‐cost option that empowers nurses to lead delirium prevention through holistic, patient‐centred care. Further studies may help clarify generalisability across different ICU settings. Trial Registration: ClinicalTrials.gov ID: NCT06403410

  • Open Access

    COMPARISON OF HIGH-FLOW NASAL OXYGEN AND CONVENTIONAL LOW-FLOW OXYGEN DURING ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY UNDER SEDATION IN GERIATRIC AND ADULT PATIENTS

    by Zekeriya Ervatan, Nihan Altintepe Başkurt, Serencan Özalp, Melike Duman, Mehmet Emin Gürbüz, Mehmet Atilla Uysal, Namigar Turgut

    Introduction: Sedated endoscopic retrograde cholangiopancreatography is associated with hypoxaemia and haemodynamic instability, particularly in geriatric patients. High-flow nasal oxygen may improve oxygenation compared with conventional oxygen therapy, yet its benefits in elderly patients undergoing endoscopic retrograde cholangiopancreatography remain unclear. Materials and Method: In this prospective randomized study, 100 adult patients undergoing elective endoscopic retrograde cholangiopancreatography were randomly assigned (1:1) to receive either High-flow nasal oxygen (50L·min⁻¹ with FiO2 0.50) or conventional oxygen therapy (4L/min.). Patients were randomly allocated into four groups: Group I:Adult (<65 years)+High-flow nasal oxygen, n=25 ), Group II:Geriatric (≥65 years)+High-flow nasal oxygen, n=25), Group III:Adult (<65 years) + conventional oxygen therapy, n=25), Group IV: Geriatric (≥65 years)+conventional oxygen therapy, n=25). The primary outcomes were hypoxaemia (SpO2≤90%) and hypotension (systolic arterial pressure <90 mmHg or ≥20% decrease from baseline). Secondary outcomes included haemodynamic variables, end-tidal CO2, sedative consumption, and recovery time. Results: High-flow nasal oxygen significantly reduced hypoxaemic events, particularly in geriatric patients (p<0.05). SpO2 values remained more stable in the elderly High-flow nasal oxygen group, especially at the 15th and 30th minutes. End-tidal CO2 remained within physiological ranges in all groups. Systolic arterial pressure decreased in all groups at 5 minutes; reductions were more pronounced in geriatric patients irrespective of oxygenation strategy. Recovery time was shorter in adults receiving High-flow nasal oxygen (p<0.05). Conclusion: High-flow nasal oxygen improves oxygenation and reduces hypoxaemia during sedated endoscopic retrograde cholangiopancreatography, with the greatest benefit observed in geriatric patients. However, advanced age remains an independent risk factor for haemodynamic instability. Careful sedative titration and close monitoring are essential in elderly patients. Keywords: Cholangiopancreatography, Endoscopic Retrograde; Oxygen Inhalation Therapy; Aged; Oxygen Saturation; Hypotension; Procedural Sedation.

  • Iatrogenic systemic botulism after intragastric botulinum neurotoxin injection: Case report

    by Bekir Burak Kılboz, Zekeriya Ervatan, Rıdvan Dumlu, Onur Akan

    Background and purpose: The recent off‐label use of botulinum neurotoxin (BoNT) for intragastric obesity treatment has led to 67 cases of systemic botulism in Türkiye, Germany, Austria and Switzerland. This case report highlights the potential risks and adverse effects associated with this treatment.Case report: A 36‐year‐old female presented to the emergency room with shortness of breath, fatigue, difficulty in eating and holding her head, constipation and double vision after receiving intragastric BoNT injection for obesity treatment. She had bilateral orbicularis oculi weakness, facial diplegia, weak tongue, masseter, neck and extremity muscles. Electromyography showed a presynaptic type neuromuscular junction disorder. The patient was admitted to the intensive care unit and administered botulinum heptavalent equine‐derived antitoxin, but the medication had to be stopped due to a reaction. The patient was started on pyridostigmine for symptomatic treatment and was transferred to an inpatient clinic after minimal improvement. She was discharged after 7 days of follow‐up.Conclusion: Clinicians should be cautious of the potential risks of intragastric BoNT injection for obesity treatment and consider systemic botulism as a potential adverse effect. Antitoxin treatment should be considered in clinically progressing patients despite negative botulinum toxin testing.